PHASE I TRIAL OF RP60475 ADMINISTERED AS A 1/2 HOUR INFUSION EVERY 21 DAYS

RP60475 的 I 期试验每 21 天注射 1/2 小时

• 批准号: 3766290
• 负责人: JOHN ECKARDT
• 金额: --
• 依托单位: UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3766290
• 关键词: DNA topoisomerases; antineoplastics; clinical trials; drug administration rate /duration; drug screening /evaluation; enzyme inhibitors; human subject; human therapy evaluation; neoplasm /cancer chemotherapy

This is a phase I study to examine the antineoplastic effect of RP60475 (an inhibitor of topoisomerase) in patients with solid tumors who are refractory to all forms of standard therapy.

这是一项I期研究，旨在检查RP 60475的抗肿瘤作用 (an拓扑异构酶抑制剂）的实体瘤患者中， 对所有形式的标准疗法都是难治性的。